Key facts
- This page summarizes Valerie Odegard's Form 4 filing for Odyssey Therapeutics, Inc. (ODTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 11 May 2026, 20:30.
Valerie Odegard - 07 May 2026 Form 4 Insider Report for Odyssey Therapeutics, Inc. (ODTX)
- Reporting relationship
- Director
- Issuer ticker
- ODTX
- Reported as of
- 07 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 May 2026, 20:30:16 UTC
- Prior SEC filing
- 04 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jolie M. Siegel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Valerie Odegard filed Form 4 for Odyssey Therapeutics, Inc. (ODTX) on 11 May 2026.
Change
- Previous filing in this sequence was filed on 04 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001832432
Primary reporting owner
Odegard Valerie
- Relationship
- Director
- Address
- C/O ODYSSEY THERAPEUTICS, INC., 51 SLEEPER STREET, SUITE 800, BOSTON
- Signature
- /s/ Jolie M. Siegel, Attorney-in-Fact
- Signature date
- 11 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ODTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +27,393
- Change %
- Price
- $0.000000*
- Shares after
- 27,393
- Date
- 07 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,393
- Exercise price
- $18.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.